CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders, announced its financial results for the fourth quarter and full year ended December 31, 2025, along with significant corporate updates. The company reported a net loss of approximately $27 million for the year, an increase from $16.2 million in 2024. Despite the loss, CervoMed highlighted several positive developments, including the successful reporting of Phase 2b clinical data for its lead drug candidate, neflamapimod, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference. The company has also obtained alignment with the FDA and global regulators on the design of its planned Phase 3 trial for patients with dementia with Lewy bodies (DLB). This trial is expected to initiate in the second half of 2026, pending sufficient funding. CervoMed anticipates multiple catalysts in 2026, including topline data from ongoing Phase 2a trials in ischemic stroke recovery and primary progressive aphasia, as well as the initiation of the EXPERTS-ALS trial in amyotrophic lateral sclerosis. The company ended 2025 with approximately $20.9 million in cash, which it believes will fund operations for about six months. CervoMed's strategic focus on advancing its clinical programs and strengthening its intellectual property portfolio positions it for potential growth in the coming year.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.